Abundant Produce signs new China-Australia export deal
Published 04-APR-2018 12:27 P.M.
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Abundant Natural Health, which is 100% owned by Abundant Produce Limited (ASX:ABT), this morning informed the market it has entered into an International Supply Agreement with Jatenergy Limited (JAT).
The agreement, covering a period of 24 months from commencement with two 24-month options to renew, will include the Active Lyco TM Face Range and Magnesium Body and Salt Skin Range totalling six SKUs, which will be expanded in line with consumer demand.
JAT is an end-to-end export service provider offering a fast, cost effective, one-stop solution for Australian companies seeking to launch and build their brands in China. Recently, JAT’s shareholders approved the takeover of Golden Koala — a producer of Australian-made infant formula and milk products sold into China — further strengthening its position as a China-Australia border specialist.
ANH CEO Shanan Birkin said: “On the back of our recent HealthOne agreement, this is an exciting expansion of the distribution channel into the Chinese consumer marketplace.
“JAT will promote ANH’s scientifically developed, natural health range of face treatments and body creams and sprays to its vast consumer network in China. We intend to start fulfilment of the JAT supply chain immediately.”
JAT Executive Director, Wilton Yao also commented: “As ANH’s exclusive Chinese marketplace partner, JAT intends to create and facilitate strong relationships on behalf of ANH in this growing consumer market. Product quality and provenance are critical factors in supplying the Chinese market and ANH’s natural range meets these requirements 100%.
“Key to promoting ANH’s range in China is its focus on the scientific development of its products in collaboration with The University of Sydney and The University of NSW.”
ANH recently announced its partnership with HealthOne, which will represent ANH’s products in Australian pharmacies and specialist health focused outlets.
“ANH has partnered distribution and marketing partners, HealthOne and JAT, to capitalise on their deep operating understanding and knowledge of their respective marketplaces, which will ultimately drive sales growth,” Birkin said.
“We’re confident that HealthOne and JAT can successfully promote and sell our unique science and research-backed natural actives in the Australian and Chinese markets.”
ABT is a speculative stock and investors should seek professional financial advice if considering this stock for their portfolio.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.